alpha 2A-adrenergic receptor Agonists
1 drugsAbout alpha 2A-adrenergic receptor
The alpha 2A-adrenergic receptor is a G protein-coupled receptor in the alpha-adrenergic family, primarily located within the central nervous system. It regulates neurotransmitter release, especially norepinephrine, influencing attention, cognition, and blood pressure.
The α2A-adrenergic receptor is a therapeutic target for neurological and psychiatric conditions; however, there is currently no genetic evidence directly linking this receptor to specific diseases.
INTUNIV (Takeda) is the only FDA-approved drug targeting this receptor, a small molecule approved in 2009 for CNS indications. Further research may lead to novel treatments where current therapies are insufficient.
Top alpha 2A-adrenergic receptor Drugs
Takeda is the only company with an approved drug (INTUNIV) targeting the alpha 2A-adrenergic receptor.
The market is not highly competitive, presenting an opportunity for new entrants to develop novel therapies.
alpha 2A-adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 2A-adrenergic receptor, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing treatments.
alpha 2A-adrenergic receptor Clinical Trials 29 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha 2A-adrenergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 12 | 10 | 1 | 1 | 91% |
| Phase 3 | 8 | 7 | 0 | 1 | 100% |
| Phase 4 | 7 | 7 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 2A-adrenergic receptor Drug Approval Timeline (2009 - 2009)
The first and only drug, INTUNIV, was approved in 2009, indicating a long period without new approvals.
The lack of recent approvals suggests potential for innovation and unmet needs in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 14 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha 2A-adrenergic receptor. A trial counts if an approved drug acting on alpha 2A-adrenergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.